An extracellular vesicle component as a candidate to control cryptococcosis

Active Project Grant Awarded Last action

Award ID
R01AI183314
Recipient
Awarding agency
Obligated
$612,092

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 53% complete
Place of performance
2135 N Keene Rd, Clearwater, FL 33763, USA

Award details come from USAspending.gov.

Description

Summary fungal diseases are a major threat to immunocompromised patients. Cryptococcosis, caused by members of the cryptococcus genus, is responsible for nearly 200,000 deaths worldwide annually. Immunocompromised individuals are the primary population that develop cryptococcal meningoencephalitis, a 100% fatal condition if left untreated. C. Neoformans, the most common causative agent of cryptococcosis, has recently been classified as a critical threat by the world health organization. Despite their devastating impact on human health, fungal diseases have been consistently neglected, as demonstrated by the lack of available antifungal vaccines and our limited antifungal armamentarium. The rodrigues and nosanchuk laboratories have collaborated actively for over 15 years in the field of fungal infections and have extensively characterized fungal extracellular vesicles (EVS) in various models. EVS play crucial roles in fungal physiology and pathogenesis. Recently, we discovered that the tripeptide isoleucine-proline-isoleucine (IPI), a small molecule component of EVS, effectively controls cryptococcal infection in an invertebrate host. IPI acts as an inhibitor of dipeptidyl peptidase 4 (DPP4), which plays a role in fungal pathogenesis, as well as in host physiology, by regulating insulin and glucose. In this proposal, we aim to investigate the participation of IPI and DPP4 in fungal immunopathogenesis through three specific aims. Aim 1 will explore the protective mechanisms of IPI in animal models of cryptococcosis. Aim 2 focuses on understanding the roles of fungal and host DPP4 in disease progression, including their impact on glucose metabolism and the immune response. Aim 3 seeks to determine the relevance of IPI and DPP4 in other fungal models. Successful completion of this project will provide a comprehensive characterization of a novel candidate for combating cryptococcosis and perhaps other diseases. Furthermore, we anticipate gaining insights into the connection between DPP4 and fungal pathogenesis. This proposal aims to foster intercontinental collaboration and enhance the capabilities of fiocruz, the brazilian institution leading this collaborative effort.

Transactions

Action Obligated Date
Amendment $134,240
Amendment $130,212
Amendment $115,880
Amendment $115,880
Amendment -$115,880
Amendment -$115,880
Amendment -$115,880
Amendment $115,880
Amendment $115,880
Amendment $115,880
Original award $115,880
Show all 11

Quick answers

Who received award R01AI183314?

R01AI183314 was awarded to Fundacao Oswaldo Cruz by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 21, 2024.

How much is award R01AI183314 worth?

$612,092 has been obligated on R01AI183314.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award